Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRL-301 in R/R Autoimmune Diseases
NCT05859997Phase 1Enrolling by invitation
- Sponsor
- BRL Medicine Inc.
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BRL-301 in systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic sclerosis (SSc) and 3 more, sponsored by BRL Medicine Inc. Primary endpoint: Safety and efficacy outcomes at 1 year. Started May 2023; status: enrolling by invitation.
02
Drugs
BRL-301
03
Conditions
systemic lupus erythematosus (SLE)Sjogren's syndromesystemic sclerosis (SSc)inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05859997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859997.